Abbott Laboratories（ABT）株式概要
アボット・ラボラトリーズは、その子会社とともに、世界中でヘルスケア製品の発見、開発、製造、販売を行っている。 詳細
ABT Community Fair Values
Create NarrativeSee what 259 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$113.88
FV
24.8% 割安 内在価値ディスカウント6.57%
Revenue growth p.a.
212
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Abbott Laboratories 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$85.60 |
| 52週高値 | US$139.06 |
| 52週安値 | US$81.97 |
| ベータ | 0.65 |
| 1ヶ月の変化 | -4.31% |
| 3ヶ月変化 | -24.99% |
| 1年変化 | -35.92% |
| 3年間の変化 | -17.85% |
| 5年間の変化 | -21.68% |
| IPOからの変化 | 23,274.50% |
最新ニュース
ナラティブの更新 • May 12
ABT: Medtech Pipeline And Dividend Record Will Support Future Repricing
Analysts have trimmed Abbott Laboratories' consolidated price target by $1, reflecting a slightly higher discount rate, a marginally lower revenue growth outlook, a very small adjustment to profit margin assumptions, and a modestly lower future P/E multiple in light of several recent target cuts and a removal from a conviction list. Analyst Commentary Recent Street research on Abbott Laboratories has tilted more cautious, with a series of price target reductions and a removal from a major conviction list.Seeking Alpha • May 09
Abbott Laboratories Is On Sale, Don't Overlook It
Summary Abbott Laboratories is trading at a 27% discount to fair value, offering a compelling entry point for long-term investors. ABT's Medical Devices and Diagnostics segments drive robust growth, with the Exact Sciences acquisition adding market-leading oncology diagnostics. Consensus forecasts 9.1% annual EPS growth through 2028, supporting continued 7%-8% dividend growth and a 54-year streak. Litigation over infant formula and Exact Sciences' integration pose risks, but ABT's fundamentals and earnings growth underpin a projected 45% upside by 2027. Read the full article on Seeking AlphaRecent updates
ナラティブの更新 • May 12
ABT: Medtech Pipeline And Dividend Record Will Support Future Repricing
Analysts have trimmed Abbott Laboratories' consolidated price target by $1, reflecting a slightly higher discount rate, a marginally lower revenue growth outlook, a very small adjustment to profit margin assumptions, and a modestly lower future P/E multiple in light of several recent target cuts and a removal from a conviction list. Analyst Commentary Recent Street research on Abbott Laboratories has tilted more cautious, with a series of price target reductions and a removal from a major conviction list.Seeking Alpha • May 09
Abbott Laboratories Is On Sale, Don't Overlook It
Summary Abbott Laboratories is trading at a 27% discount to fair value, offering a compelling entry point for long-term investors. ABT's Medical Devices and Diagnostics segments drive robust growth, with the Exact Sciences acquisition adding market-leading oncology diagnostics. Consensus forecasts 9.1% annual EPS growth through 2028, supporting continued 7%-8% dividend growth and a 54-year streak. Litigation over infant formula and Exact Sciences' integration pose risks, but ABT's fundamentals and earnings growth underpin a projected 45% upside by 2027. Read the full article on Seeking Alphaナラティブの更新 • Apr 23
ABT: AF Portfolio And Dividend Track Record Will Support Future Repricing
Analysts have trimmed Abbott Laboratories' implied fair value estimate to $118.64 from $131.44. This reflects a series of recent price target reductions as they factor in updated growth, margin and P/E assumptions.ナラティブの更新 • Apr 09
ABT: AF Portfolio And Dividend Track Record Will Support Future Upside
Abbott Laboratories' updated analyst price target reflects a modest reset, with fair value moving from $132.64 to $131.44 as analysts factor in higher assumed revenue growth of 10.24%, a lower profit margin of 15.60% and a slightly richer future P/E of 30.91x. Analyst Commentary Recent research on Abbott Laboratories points to an active debate around how much investors should pay for the stock, with several price target changes clustered over the past few months.ナラティブの更新 • Mar 26
ABT: AF Portfolio Advancements And Dividend Streak Will Support Future Upside
Analysts have trimmed Abbott Laboratories' fair value estimate by about $0.70 to $132.64. This reflects a series of recent target cuts across the Street, even as they continue to reference generally healthy medtech sector fundamentals.ナラティブの更新 • Mar 11
ABT: AF Portfolio Progress And Dividend Streak Will Drive Future Upside
Analysts have trimmed their average price targets on Abbott Laboratories by a few dollars, reflecting slightly higher required returns and refreshed assumptions on fair value, while still grounding their views in recent research that includes both target cuts and at least one upward revision. Analyst Commentary Recent research on Abbott Laboratories gives you a mixed but useful read on how the Street is thinking about valuation, execution, and growth.ナラティブの更新 • Feb 24
ABT: Exact Sciences Deal And AF Portfolio Will Reshape Future Upside
Analyst targets on Abbott Laboratories have moved lower by double digit dollar amounts, with multiple firms trimming their price objectives in U.S. dollars as they factor in updated assumptions on discount rates, long term revenue growth, margins and future P/E expectations. Analyst Commentary Recent Street research on Abbott Laboratories reflects a mix of caution on valuation and optimism around the company’s longer term positioning, with several firms resetting price targets and one firm upgrading the stock.ナラティブの更新 • Feb 10
ABT: Exact Sciences Deal Will Reshape Testing Franchise And Future Upside
Analysts have trimmed their fair value estimate for Abbott Laboratories by about $3 to roughly $133. This reflects modestly softer revenue growth assumptions, a slightly lower future P/E multiple near 30x, and recent reductions in price targets across several firms, even as some still highlight the pending Exact Sciences deal as a key part of their thesis.ナラティブの更新 • Jan 26
ABT: Exact Sciences Acquisition Will Shape Future Earnings Mix And Upside Potential
Analysts have reduced their fair value estimate for Abbott Laboratories by about $8 to $136.47, reflecting a series of recent price target cuts that incorporate slightly adjusted growth, discount rate and P/E assumptions, along with expectations for a modestly higher profit margin profile. Analyst Commentary Recent research updates show a mix of optimism and caution around Abbott Laboratories, with several firms adjusting price targets and factoring in the pending Exact Sciences acquisition.ナラティブの更新 • Jan 11
ABT: Exact Sciences Deal And Legal Wins Will Support Future Upside
Narrative Update Overview The updated analyst work on Abbott Laboratories reflects a small increase in the implied fair value to about $144.75. Analysts point to a tighter discount rate, steady growth and margin assumptions, and a blended view of recent price target changes that factor in medical devices momentum, the pending Exact Sciences deal, and reduced legal overhangs.分析記事 • Jan 03
Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT)
What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...ナラティブの更新 • Dec 27
ABT: Exact Sciences Deal And Legal Wins Will Drive Future Returns
Analysts modestly raised their average price target for Abbott Laboratories to about $144 per share, citing resilient mid-single digit organic revenue growth, double digit earnings power supported by a diversified healthcare portfolio, accelerating momentum in Medical Devices despite some near term lumpiness, and potential strategic upside from the pending Exact Sciences acquisition at a premium takeout valuation. Analyst Commentary Street research remains broadly constructive on Abbott, with recent notes highlighting both upside drivers and areas of near term scrutiny as investors digest the Exact Sciences transaction and mixed quarterly optics.ナラティブの更新 • Dec 12
ABT: Exact Sciences Deal And Legal Wins Will Drive Future Upside
Analysts made a modest adjustment to their Abbott Laboratories price targets, with estimates moving in a roughly $2 range around the mid-$140s as they balanced optimism around the pending Exact Sciences acquisition, resilient device driven growth, and favorable legal developments against some near term lumpiness in non device segments. Analyst Commentary Research coverage around Abbott remains largely constructive, with most views anchored on a durable devices growth profile, incremental benefits from the proposed Exact Sciences transaction, and diminishing legal overhangs.ナラティブの更新 • Nov 28
ABT: Exact Sciences Acquisition And Legal Wins Will Drive Medium-Term Upside
Abbott Laboratories’ analyst price target saw a modest decrease to $144.43 as analysts point to shifting expectations around profit margin and a slightly higher discount rate. This development is tempered by optimism for ongoing revenue growth and stability in core medical device performance.ナラティブの更新 • Nov 14
ABT: Momentum From Legal Win And Product Approvals Will Support Future Gains
Analysts have modestly revised their price targets for Abbott Laboratories, with recent updates ranging from $142 to $146 per share. They cite strong momentum in Medical Devices and a resilient, diversified business model, despite varied performance across business segments.分析記事 • Nov 05
Abbott Laboratories' (NYSE:ABT) Earnings Are Weaker Than They Seem
Abbott Laboratories ( NYSE:ABT ) announced strong profits, but the stock was stagnant. Our analysis suggests that...ナラティブの更新 • Oct 31
ABT: Legal Wins And Device Momentum Will Support Durable Growth Ahead
Abbott Laboratories' average analyst price target experienced a modest increase to approximately $144.47. Analysts cited positive legal developments and continued momentum in the Medical Devices segment as key factors supporting the adjustment.ナラティブの更新 • Oct 16
Expanding Emerging Markets And Diagnostics Will Drive Prospects Despite Headwinds
Analysts have modestly increased their price target for Abbott Laboratories from $142.48 to $144.40, citing resilient growth in medical devices and expectations for steady double-digit earnings growth, even though there may be some near-term variability across business segments. Analyst Commentary Recent research notes reflect a mix of optimism and caution from analysts following Abbott Laboratories' latest results and updates to price targets.分析記事 • Sep 15
There's No Escaping Abbott Laboratories' (NYSE:ABT) Muted Earnings
With a price-to-earnings (or "P/E") ratio of 16.7x Abbott Laboratories ( NYSE:ABT ) may be sending bullish signals at...Seeking Alpha • Apr 16
Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices
Summary I reiterate a "Strong Buy" rating on Abbott Laboratories, driven by strong growth in medical device and pharma markets, with a fair value of $160 per share. Abbott reported 6.9% organic revenue growth and 8.3% growth excluding COVID testing, driven by 12.6% growth in medical devices and 7.8% in pharma. Abbott's diversified global supply chain and 25 new products in the pipeline position it well to navigate tariff impacts and drive future growth. Despite geopolitical risks in China, Abbott's cost management and margin expansion support the ABT stock double-digit EPS growth guidance for FY25. Read the full article on Seeking AlphaSeeking Alpha • Mar 16
Abbott Laboratories Basking In A Sharp Turn In Sentiment
Summary Abbott Laboratories' stock has surged 25% in eight months, outperforming peers on strong medical device growth and perhaps market rotation to names with less perceived macro and geopolitical risk. Fourth quarter results showed 9% organic revenue growth, with medical devices leading at 14%, and improved profit margins. Abbott's medical device business is executing well, with double-digit growth in structural heart and diabetes, and above-peer results across most of the business. An important legal victory could signal lower overall risk in its infant nutrition litigation, while a lackluster trial result from a rival could re-energize the outlook for TriClip. Valuation is more challenging now, as it takes a pretty aggressive bull-case model to find significant fundamentals-driven upside. Read the full article on Seeking AlphaSeeking Alpha • Jan 23
Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)
Summary Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month. The company looks set up to deliver double-digit annual adjusted diluted EPS growth for the foreseeable future. Abbott Laboratories enjoys an AA- credit rating from S&P on a stable outlook. Shares of the healthcare stock appear to be modestly discounted. Abbott Laboratories could be positioned for 10% annual total returns by the end of 2027. Read the full article on Seeking Alpha株主還元
| ABT | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | -2.1% | -3.5% | 1.5% |
| 1Y | -35.9% | -22.1% | 28.6% |
業界別リターン: ABT過去 1 年間で-22.1 % の収益を上げたUS Medical Equipment業界を下回りました。
リターン対市場: ABTは、過去 1 年間で28.6 % のリターンを上げたUS市場を下回りました。
価格変動
| ABT volatility | |
|---|---|
| ABT Average Weekly Movement | 3.6% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
安定した株価: ABT 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: ABTの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1888 | 115,000 | Robert Ford | www.abbott.com |
アボット・ラボラトリーズは、その子会社とともに、世界中でヘルスケア製品の発見、開発、製造、販売を行っている。事業セグメントは4つ：確立された医薬品、診断薬、栄養製品、医療機器。同社は、膵外分泌機能不全、過敏性腸症候群または胆道けいれん、肝内胆汁うっ滞またはうつ症状、婦人科疾患、ホルモン補充療法、脂質異常症、高血圧症、甲状腺機能低下症の治療薬としてジェネリック医薬品を提供している、高血圧症、甲状腺機能低下症、高トリグリセリド血症、メニエール病および前庭性めまい症、疼痛、発熱、炎症、片頭痛、抗感染症薬クラリスロマイシン、インフルエンザワクチン、大腸の生理的リズムを調整する製品を提供する。また、免疫測定、臨床化学、血液学、輸血血清学検査の分野における検査および輸血医療システム、患者サンプルからのDNAおよびRNAの抽出、精製、調製を自動化し、感染因子を検出・測定する分子診断ポリメラーゼ連鎖反応装置システムも提供している；POCシステム、血液ガス、化学、電解質、凝固、免疫測定用カートリッジ、迅速診断ラテラルフロー検査製品、HIV、SARS-CoV-2、インフルエンザAおよびB、RSV、溶連菌Aの分子POC検査、心代謝検査システム、薬物およびアルコール検査。また、小児用および成人用栄養製品、乳児用粉ミルク、循環器疾患治療用のリズム管理、電気生理学、心不全、血管、構造心臓機器、グルコースおよび血糖モニタリングシステムなどの糖尿病ケア製品、神経調節機器も提供している。以前はアボット・アルカロイド・カンパニーとして知られ、1915年にアボット・ラボラトリーズに社名を変更した。アボット・ラボラトリーズは1888年に設立され、イリノイ州アボット・パークに本社を置いている。
Abbott Laboratories 基礎のまとめ
| ABT 基礎統計学 | |
|---|---|
| 時価総額 | US$149.10b |
| 収益（TTM） | US$6.25b |
| 売上高(TTM) | US$45.13b |
23.8x
PER（株価収益率3.3x
P/SレシオABT は割高か？
公正価値と評価分析を参照収益と収入
| ABT 損益計算書（TTM） | |
|---|---|
| 収益 | US$45.13b |
| 売上原価 | US$19.63b |
| 売上総利益 | US$25.50b |
| その他の費用 | US$19.25b |
| 収益 | US$6.25b |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 3.59 |
| グロス・マージン | 56.50% |
| 純利益率 | 13.85% |
| 有利子負債／自己資本比率 | 64.8% |
ABT の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
2.9%
現在の配当利回り68%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/31 00:52 |
| 終値 | 2026/05/29 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Abbott Laboratories 24 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。52
| アナリスト | 機関 |
|---|---|
| David Toung | Argus Research Company |
| Adam Feinstein | Barclays |
| Matthew Miksic | Barclays |